Novo Nordisk A/S
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial
The Roche Holding AG headquarters on April 11, 2025, in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images Swiss pharmaceutical firm Roche is targeting becoming a top three obesity player globally, posing a potential rival to heavyweights Novo Nordisk and Eli Lilly as it advances one of its experimental weight-loss drugs to […]
Read More
Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs
A rendering of Eli Lilly’s manufacturing facility in Houston, Texas. Courtesy: Eli Lilly Eli Lilly on Tuesday said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company’s pipeline of so-called small molecule drugs, including its closely watched experimental obesity pill. It is the second in […]
Read More
Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
Thomas Fuller | SOPA Images | Lightrocket | Getty Images Pfizer on Monday said it would buy weight loss drugmaker Metsera in an up to $7.3 billion deal, including future payments, as it scrambles to win a slice in the booming obesity drug market. Pfizer said it will pay an initial $47.50 a share in […]
Read More
Stocks making the biggest premarket moves: Intel, Novo Nordisk, Bullish, Cracker Barrel and more
Check out the companies making the biggest moves in premarket trading: Intel — The semiconductor maker soared 30% after Nvidia said it will invest $5 billion in Intel to co-develop data center and PC products. Nvidia added 3%, one day after it lost 2.6%. Novo Nordisk — The Danish drugmaker jumped 7.6% after late-stage results […]
Read More
Novo Nordisk shares pop 5% after Wegovy pill trial shows ‘significant’ weight reduction
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Novo Nordisk said Wednesday that late-stage trial results […]
Read More
Eli Lilly pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Wednesday said its experimental pill outperformed Novo Nordisk‘s own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes. The […]
Read More
Jim Cramer says Eli Lilly’s obesity pill could be more of a ‘lifetime drug’ than shots
Don’t count out Eli Lilly’s oral GLP-1 drug for obesity and diabetes just yet, according to CNBC’s Jim Cramer . That was his takeaway following the latest study involving Lilly’s orforglipron, the experimental pill that has been the subject of Wall Street debate since weight-loss data released in early August came in below investor expectations. […]
Read More
Wegovy-maker Novo Nordisk to cut around 9,000 jobs
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images Danish pharmaceutical giant Novo Nordisk on Wednesday announced plans to cut around 9,000 roles, or roughly 11.5% of its global workforce. “Novo Nordisk today announced a company-wide transformation to simplify its organisation, improve the speed […]
Read More
Eli Lilly to build $5 billion Virginia facility to boost production of targeted cancer drugs, other treatments
Eli Lilly Biotechnology Center is shown in San Diego, California, March 1, 2023. Mike Blake | Reuters Eli Lilly on Tuesday said it will spend $5 billion to build a manufacturing facility in Goochland County, Virginia, to boost production capacity for targeted cancer drugs and other treatments — the first in a string of new […]
Read More
Novo Nordisk flags drug trial promise amid hunt for next weight-loss blockbuster
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Novo Nordisk on Wednesday flagged promising late-stage […]
Read More